Pre-earnings options volume in Capricor Therapeutics (CAPR) is 5.8x normal with puts leading calls 8:5. Implied volatility suggests the market is anticipating a move near 40.9%, or 0c, after results are released. Median move over the past eight quarters is 8.0%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics, Inc. (CAPR) Q3 Earnings Cheat Sheet
- Capricor Therapeutics announces publication in Biomedicines on Deramiocel
- Capricor Therapeutics management to meet with Piper Sandler
- Largest borrow rate increases among liquid names
- Capricor Therapeutics’ Deramiocel Progress and FDA Clarity Underpin Buy Rating